Postdoctoral Training in Neurodevelopmental Disabilities Research
Funded by a T32 Award from the National Institute of Neurological Disorders and Stroke (NINDS), this 2-year program is integrated into the District of Columbia Intellectual and Developmental Disabilities Resource Center (DC-IDDRC) at the Children’s Research Institute of Children’s National Hospital in Washington, D.C
Postdoctoral position in lung diseases in Linda Crnic Institute for Down Syndrome
The Michael Yeager lab in the Linda Crnic Institute for Down Syndrome is seeking a postdoctoral fellow. The current work is focused on understanding how bronchus-associated lymphoid tissue contributes to the clinical impacts of trisomy 21, including predisposition to severe respiratory infection and pulmonary hypertension.
The position requires a candidate with experience in cell and molecular vascular biology methods as well as in rodent models.
Postdoctoral Researcher, Knoebel Institute for Healthy Aging, Denver, CO, USA
The Knoebel Institute for Healthy Aging has an exciting opportunity for a Postdoctoral Researcher to join Dr. Aurélie Ledreux’s laboratory located at the University of Denver (DU) in Denver, CO. The Ledreux lab is looking for a motivated and technically gifted Postdoctoral fellow to play a key role in a project funded by an R01 from the National Institutes on Aging. The postdoctoral fellow is expecting to engage in studies investigating the noradrenergic dysfunction in Down syndrome, using intracranial administration of Designer Receptors (DREADDs) and exosomes. Preference will be given to individuals with previous experience in stereotactic surgery in mice.
Postdoctoral Fellows, Espinosa and Sullivan Labs, Denver, CO, USA
The Espinosa and Sullivan labs in the Linda Crnic Institute for Down Syndrome are seeking postdoctoral fellows.
We employ an integrated approach including functional genomics, mechanistic studies, and animal research to
make biological discoveries with clear translational potential. Our current work is focused on understanding how
hyperactivation of interferon signaling in people with Down syndrome contributes to the clinical impacts of trisomy
21, including predisposition to autoimmune conditions, Alzheimer’s Disease, leukemia, and protection from solid
malignancies (e.g. Sullivan et al., eLIFE 2016; Powers et. al., Nature Communications 2019; Waugh et al., Cell
Reports 2019). We currently have numerous NIH-funded positions available